Corton Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Corton Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,714	Closed	-$261K	–	399
2024 Q4	$261K	Buy	+4,714	New	+$214K	0.15%	161

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Corton Capital's TARS Position: Q1 2025 in Review

Corton Capital sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 4,714 shares — an estimated $261K sold.

Corton Capital first reported a position in TARS in Q4 2024 and held it in 1 quarter. The position peaked at $261K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Corton Capital reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Corton Capital sold 4,714 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $261K.
Corton Capital first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Corton Capital's Tarsus Pharmaceuticals position peaked at $261K in Q4 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.